medical guideline
首页
中医/中西医结合指南
肿瘤学指南
泌尿外科指南
关于我们
郑重声明
联系我们
首页
肿瘤学指南
检索结果
人体系统
运动
骨肿瘤
软组织肿瘤
骨与软组织肿瘤
硬纤维瘤
骶尾部畸胎瘤
神经
中枢神经系统肿瘤
嗜铬细胞瘤和副神经节瘤
副神经节瘤
胶质细胞瘤
前庭神经鞘瘤
星形胶质细胞瘤和少突胶质细胞瘤
弥漫性胶质瘤
神经纤维瘤
神经细胞瘤
神经内分泌肿瘤
内分泌
甲状腺肿瘤
垂体肿瘤
肾上腺肿瘤
甲状旁腺肿瘤
胸腺肿瘤
神经内分泌肿瘤
循环
心脏肿瘤
淋巴瘤
骨髓瘤
白血病
血液肿瘤
血管瘤
呼吸
肺癌
鼻咽癌
喉部肿瘤
下咽癌
鼻腔和副鼻窦癌
呼吸道肿瘤
鼻颅咽管瘤
淋巴管肌瘤
消化
胰腺肿瘤
口腔癌
肛门癌
口咽癌
胆囊癌
胆管肿瘤
直肠癌
结肠癌
胃癌
小肠癌
肝癌
大肠肿瘤
唾液腺癌
阑尾肿瘤
食管肿瘤
肝肿瘤
壶腹肿瘤
肝胆癌
结直肠肿瘤
食管胃肿瘤
胃肠道肿瘤
消化道肿瘤
泌尿
膀胱肿瘤
肾癌
脐尿管癌
尿路上皮癌
肾血管平滑肌脂肪瘤
泌尿生殖肿瘤
生殖
女性
子宫肿瘤
卵巢肿瘤
乳腺肿瘤
阴道肿瘤
输卵管癌
外阴癌
妊娠滋养细胞肿瘤
妇科肿瘤
男性
前列腺肿瘤
性索间质瘤
睾丸肿瘤
阴茎癌
男性乳腺肿瘤
泌尿生殖肿瘤
其他
症状管理
治疗方案
诊断/检测/评估方法
预防和筛查
COVID-19大流行癌症患者相关指导建议
皮肤肿瘤
黑色素瘤
头颈部肿瘤
康复营养
生育能力
体力活动
心理健康
腹膜肿瘤
实体瘤
胸部肿瘤
长期监测
Cowden综合征
转诊
遗传性癌症综合征
癌症患者其他类问题管理
寡转移性疾病
基因测序
易感基因变异的分类
外科肿瘤
罕见癌症
不明原因癌症
纤维瘤
腹部肿瘤
老年肿瘤
儿童/青少年肿瘤
人类微生物组与癌变
检索结果
按关键字
按标题
按关键词
按摘要
按作者
按期刊
按发表年份
共搜索到
73条
与
ovarian
有关的结果
The 2020 Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
2021年 发布于
Journal of Gynecologic Oncology
32卷 第2期
所属人体系统：
其他
|
腹膜肿瘤
Japan Society of Gynecologic Oncology
The Fifth Edition of the Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer Was Published in 2020. the Guidelines Contain 6 Chapters-namely
(1) Overview of the Guidelines
(2) Epithelial Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(3) Recurrent Epithelial Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(4) Borderline Epithelial Tumors of the Ovary
(5) Malignant Germ Cell Tumors of the Ovary
and (6) Malignant Sex Cord-stromal Tumors. Furthermore
the Guidelines Comprise 5 Algorithms-namely
(1) Initial Treatment for Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(2) Treatment for Recurrent Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(3) Initial Treatment for Borderline Epithelial Ovarian Tumor
(4) Treatment for Malignant Germ Cell Tumor
and (5) Treatment for Sex Cord-stromal Tumor. Major Changes in the New Edition Include the Following: (1) Revision of the Title to "guidelines for the Treatment of Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer"
(2) Involvement of Patients and General (male/female) Participants in Addition to Physicians
Pharmacists
and Nurses
(3) Clinical Questions (CQs) in the PICO Format
(4) Change in the Expression of Grades of Recommendation and Level of Evidence in Accordance with the GRADE System
(5) Introduction of the Idea of a Body of Evidence
(6) Categorization of References According to Research Design
(7) Performance of Systematic Reviews and Meta-analysis for Three CQs
and (8) Voting for Each CQ/recommendation and Description of the Consensus.
指南简介
原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma
2021年 发布于
Current Oncology
28卷 第2期
所属人体系统：
其他
|
腹膜肿瘤
Ontario Health (Cancer Care Ontario)
Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II
III
Or IV Epithelial Ovary
Fallopian Tube
Or Primary Peritoneal Carcinoma Including All Histological Types.
Methods: Consistent with the Program in Evidence-based Program's Standardized Approach
MEDLINE
EMBASE
PubMed
Cochrane Library
and PROSPERO (the International Prospective Register of Systematic Reviews) Databases
and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers.
Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall
Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy
We Recommended Olaparib (Recommendation)
Niraparib (Weak Recommendation)
Veliparib (Weak Recommendation)
and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian
Fallopian Tube
Or Primary Peritoneal Carcinoma
Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available
the Recommendations Will Be Updated as Soon as Possible.
指南简介
原文链接
The 2020 Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
2021年 发布于
Journal of Gynecologic Oncology
32卷 第2期
所属人体系统：
生殖
|
输卵管癌
Japan Society of Gynecologic Oncology
The Fifth Edition of the Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer Was Published in 2020. the Guidelines Contain 6 Chapters-namely
(1) Overview of the Guidelines
(2) Epithelial Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(3) Recurrent Epithelial Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(4) Borderline Epithelial Tumors of the Ovary
(5) Malignant Germ Cell Tumors of the Ovary
and (6) Malignant Sex Cord-stromal Tumors. Furthermore
the Guidelines Comprise 5 Algorithms-namely
(1) Initial Treatment for Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(2) Treatment for Recurrent Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(3) Initial Treatment for Borderline Epithelial Ovarian Tumor
(4) Treatment for Malignant Germ Cell Tumor
and (5) Treatment for Sex Cord-stromal Tumor. Major Changes in the New Edition Include the Following: (1) Revision of the Title to "guidelines for the Treatment of Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer"
(2) Involvement of Patients and General (male/female) Participants in Addition to Physicians
Pharmacists
and Nurses
(3) Clinical Questions (CQs) in the PICO Format
(4) Change in the Expression of Grades of Recommendation and Level of Evidence in Accordance with the GRADE System
(5) Introduction of the Idea of a Body of Evidence
(6) Categorization of References According to Research Design
(7) Performance of Systematic Reviews and Meta-analysis for Three CQs
and (8) Voting for Each CQ/recommendation and Description of the Consensus.
指南简介
原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma
2021年 发布于
Current Oncology
28卷 第2期
所属人体系统：
生殖
|
输卵管癌
Ontario Health (Cancer Care Ontario)
Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II
III
Or IV Epithelial Ovary
Fallopian Tube
Or Primary Peritoneal Carcinoma Including All Histological Types.
Methods: Consistent with the Program in Evidence-based Program's Standardized Approach
MEDLINE
EMBASE
PubMed
Cochrane Library
and PROSPERO (the International Prospective Register of Systematic Reviews) Databases
and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers.
Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall
Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy
We Recommended Olaparib (Recommendation)
Niraparib (Weak Recommendation)
Veliparib (Weak Recommendation)
and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian
Fallopian Tube
Or Primary Peritoneal Carcinoma
Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available
the Recommendations Will Be Updated as Soon as Possible.
指南简介
原文链接
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic
2021年 发布于
National Comprehensive Cancer Network
卷 第期
所属人体系统：
消化
|
胰腺肿瘤
National Comprehensive Cancer Network
Breast
ovarian
pancreatic
risk Assessment
gene
management
指南简介
原文链接
Ovarian Cancer(Guideline for Patients)
2021年 发布于
National Comprehensive Cancer Network
卷 第期
所属人体系统：
生殖
|
卵巢肿瘤
National Comprehensive Cancer Network
Patient
Epithelial
Ovarian Cancer
treatment
stage
指南简介
原文链接
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic
2021年 发布于
National Comprehensive Cancer Network
卷 第期
所属人体系统：
生殖
|
子宫肿瘤
National Comprehensive Cancer Network
Breast
ovarian
pancreatic
risk Assessment
gene
management
指南简介
原文链接
British Gynaecological Cancer Society/British Association of Gynaecological Pathology Consensus for Germline and Tumor Testing for BRCA 1/2 Variants in Ovarian Cancer in the United Kingdom
2021年 发布于
International Journal of Gynecological Cancer
31卷 第2期
所属人体系统：
生殖
|
卵巢肿瘤
British Gynaecological Cancer Society/British Association of Gynaecological Pathology
BRCA1 Protein
BRCA2 Protein
Fallopian Tube Neoplasms
Ovarian Neoplasms
指南简介
原文链接
SEOM Clinical Guideline in Ovarian Cancer (2020)
2021年 发布于
Clinical and Translational Oncology
23卷 第5期
所属人体系统：
生殖
|
卵巢肿瘤
Spanish Society of Medical Oncology
Diagnosis
Guideline
Ovarian Cancer
Treatment
指南简介
原文链接
Borderline Ovarian Tumors: French Guidelines from the CNGOF. Part 1. Epidemiology, Biopathology, Imaging and Biomarkers
2021年 发布于
Journal of Gynecology Obstetrics and Human Reproduction
50卷 第1期
所属人体系统：
生殖
|
卵巢肿瘤
Collège National Des Gynécologues Et Obstétriciens Français
Borderline Ovarian Tumor
Guidelines
指南简介
原文链接
Borderline Ovarian Tumors: French Guidelines from the CNGOF. Part 2. Surgical Management, Follow-up, Hormone Replacement Therapy, Fertility Management and Preservation.
2021年 发布于
Journal of Gynecology Obstetrics and Human Reproduction
50卷 第1期
所属人体系统：
生殖
|
卵巢肿瘤
French National College of Obstetricians and Gynecologists
Borderline Ovarian Tumor
Guidelines
指南简介
原文链接
Management of Ovarian Cancer: Guidelines of the Italian Medical Oncology Association (AIOM)
2021年 发布于
Tumori
107卷 第2期
所属人体系统：
生殖
|
卵巢肿瘤
Italian Medical Oncology Association
Epidemiology and Prevention
Guidelines
Gynecologic Oncology
Molecular Oncology
Ovarian Cancer
指南简介
原文链接
Use of Bevacizumab in Advanced Ovarian Cancer: Consensus from an Expert Panel Oncologists
2021年 发布于
Indian Journal of Gynecologic Oncology
19卷 第期
所属人体系统：
生殖
|
卵巢肿瘤
无
Advanced Ovarian Cancer
Bevacizumab
Consensus
India
Platinum-resistant Ovarian Cancer
Platinum-sensitive Ovarian Cancer
指南简介
原文链接
The 2020 Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
2021年 发布于
Journal of Gynecologic Oncology
32卷 第2期
所属人体系统：
生殖
|
卵巢肿瘤
Japan Society of Gynecologic Oncology
The Fifth Edition of the Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer Was Published in 2020. the Guidelines Contain 6 Chapters-namely
(1) Overview of the Guidelines
(2) Epithelial Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(3) Recurrent Epithelial Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(4) Borderline Epithelial Tumors of the Ovary
(5) Malignant Germ Cell Tumors of the Ovary
and (6) Malignant Sex Cord-stromal Tumors. Furthermore
the Guidelines Comprise 5 Algorithms-namely
(1) Initial Treatment for Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(2) Treatment for Recurrent Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer
(3) Initial Treatment for Borderline Epithelial Ovarian Tumor
(4) Treatment for Malignant Germ Cell Tumor
and (5) Treatment for Sex Cord-stromal Tumor. Major Changes in the New Edition Include the Following: (1) Revision of the Title to "guidelines for the Treatment of Ovarian Cancer
Fallopian Tube Cancer
and Primary Peritoneal Cancer"
(2) Involvement of Patients and General (male/female) Participants in Addition to Physicians
Pharmacists
and Nurses
(3) Clinical Questions (CQs) in the PICO Format
(4) Change in the Expression of Grades of Recommendation and Level of Evidence in Accordance with the GRADE System
(5) Introduction of the Idea of a Body of Evidence
(6) Categorization of References According to Research Design
(7) Performance of Systematic Reviews and Meta-analysis for Three CQs
and (8) Voting for Each CQ/recommendation and Description of the Consensus.
指南简介
原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma
2021年 发布于
Current Oncology
28卷 第2期
所属人体系统：
生殖
|
卵巢肿瘤
Ontario Health (Cancer Care Ontario)
Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II
III
Or IV Epithelial Ovary
Fallopian Tube
Or Primary Peritoneal Carcinoma Including All Histological Types.
Methods: Consistent with the Program in Evidence-based Program's Standardized Approach
MEDLINE
EMBASE
PubMed
Cochrane Library
and PROSPERO (the International Prospective Register of Systematic Reviews) Databases
and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers.
Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall
Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy
We Recommended Olaparib (Recommendation)
Niraparib (Weak Recommendation)
Veliparib (Weak Recommendation)
and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian
Fallopian Tube
Or Primary Peritoneal Carcinoma
Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available
the Recommendations Will Be Updated as Soon as Possible.
指南简介
原文链接
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic
2021年 发布于
National Comprehensive Cancer Network
卷 第期
所属人体系统：
生殖
|
卵巢肿瘤
National Comprehensive Cancer Network
Breast
ovarian
pancreatic
risk Assessment
gene
management
指南简介
原文链接
SEOM Clinical Guidelines in Hereditary Breast and Ovarian Cancer (2019)
2020年 发布于
Clinical & Translational Oncology
22卷 第2期
所属人体系统：
生殖
|
乳腺肿瘤
Spanish Society of Medical Oncology
Hereditary Breast
Ovarian Cancer
SEOM Guidelines.
指南简介
原文链接
ESMO Management and Treatment Adapted Recommendations in the COVID-19 Era: Gynaecological Malignancies
2020年 发布于
ESMO Open
5卷 第Suppl 3期
所属人体系统：
生殖
|
妇科肿瘤
European Society for Medical Oncology
COVID-19
Cervical Cancer
Endometrial Cancer
Ovarian Cancer
Value-based Priorities.
指南简介
原文链接
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline
2020年 发布于
American Society of Clinical Oncology
卷 第期
所属人体系统：
生殖
|
卵巢肿瘤
American Society of Clinical Oncology
Ovarian Cancer
genetic Testing
tumor Testing
epithelial
expert Consensus
指南简介
原文链接
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
2020年 发布于
American Society of Clinical Oncology
卷 第期
所属人体系统：
生殖
|
卵巢肿瘤
American Society of Clinical Oncology
Ovarian Cancer
PARP Inhibitors
Management
treatment
epithelial Ovarian
Tubal
Or Primary Peritoneal Cancer (EOC)
指南简介
原文链接
首页
1
2
3
4
下一页
尾页
共73条，每页显示
20条
50条
100条
跳转至第
页
确定
